このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms

2026年7月22日 更新者:Ziad Abd Elhady Sayed Abd Elaal、Assiut University

Predictors of Pulmonary Embolism in Patients With Interstitial Lung Diseases Presenting With Worsening Respiratory Symptoms

People with interstitial lung disease (ILD) can sometimes experience a sudden and severe worsening of their breathing. While this can be caused by a flare-up of the lung disease itself, it can also be caused by a blood clot in the lungs, known as a pulmonary embolism (PE). It is often difficult for doctors to tell the difference between these two emergencies because their symptoms, such as shortness of breath and low oxygen levels, are very similar. Traditional scoring systems used to predict blood clots are often less accurate for patients who already have chronic lung diseases like ILD.

The main goal of this observational study is to find better, more reliable ways to predict which ILD patients with worsening breathing symptoms actually have a pulmonary embolism.

Researchers will observe 70 adult patients with ILD who come to the hospital with a sudden worsening of their symptoms (such as shortness of breath, chest pain, or low oxygen) and who require a specific type of CT scan (Computed Tomography Pulmonary Angiography, or CTPA) as part of their standard medical care to check for blood clots.

The study will compare the patients whose CT scan confirms a blood clot to those whose scan does not show a clot. By comparing these two groups, the research team will evaluate various clinical signs, routine blood tests, novel inflammatory markers, and heart/lung imaging details.

Identifying strong predictors of pulmonary embolism in this specific group of patients could help doctors diagnose lung blood clots faster and more accurately, leading to better clinical decision-making and improved patient outcomes

調査の概要

詳細な説明

Interstitial lung diseases (ILDs) comprise a heterogeneous group of diffuse parenchymal lung disorders characterized by inflammation and fibrosis, often leading to progressive respiratory failure. Patients with ILD carry a heightened risk of venous thromboembolism, specifically pulmonary embolism (PE), driven by chronic inflammation, endothelial dysfunction, hypoxemia, reduced mobility, and a systemic pro-thrombotic state. The development of PE in ILD patients is associated with prolonged hospitalization, increased morbidity, and poor survival outcomes.

Diagnosing PE in this specific population remains clinically challenging because the acute manifestations, such as worsening dyspnea and hypoxemia, closely mimic those of an acute ILD exacerbation. Furthermore, conventional clinical prediction models, such as the Wells and Revised Geneva scores, frequently exhibit limited diagnostic accuracy in this cohort because respiratory distress and baseline hypoxia are already common underlying features of ILD.

To address this diagnostic gap, this prospective observational study will evaluate patients with a confirmed diagnosis of ILD who present with an acute, unexplained worsening of respiratory symptoms and undergo Computed Tomography Pulmonary Angiography (CTPA).

Comprehensive clinical, laboratory, and radiological data will be systematically collected for all participants to identify independent predictors of PE. The study workflow includes:

  • Clinical Scoring: Calculation of established pre-test probability and mortality risk scores, including the traditional and simplified Wells score, Revised Geneva score, Pulmonary Embolism Severity Index (PESI), and Simplified PESI (SPESI).
  • Laboratory Assessment: Evaluation of novel inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Additional laboratory profiling includes D-dimer, C-reactive protein (CRP), serum total protein, serum albumin, renal and liver function tests, and arterial blood gas analysis to calculate the A-a oxygen gradient.
  • Radiological & Echocardiographic Evaluation: High-Resolution CT (HRCT) will be used to quantify ILD disease severity and extent via the Warrick Score. CTPA scans will be analyzed for embolus location, right ventricular (RV) diameter, RV/LV diameter ratio, and main pulmonary artery diameter. When available, transthoracic echocardiography will assess RV size and systolic function, TAPSE, fractional area change, McConnell sign, the 60/60 sign, and inferior vena cava collapsibility.

Through multivariable logistic regression and Receiver Operating Characteristic (ROC) curve analysis, the study will compare these parameters between patients with CTPA-confirmed PE and those with negative scans. The goal is to validate the predictive strength of these biomarkers and imaging parameters, supporting the development of a disease-specific diagnostic prediction model to enhance clinical decision-making for ILD patients.

研究の種類

観察的

入学 (推定)

70

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

なし

サンプリング方法

非確率サンプル

調査対象母集団

The study population consists of adult patients (aged 18 years and older) with a confirmed diagnosis of interstitial lung disease (ILD) who are admitted to the Chest Department and Respiratory Intensive Care Unit at Assiut University Hospital, Egypt. Eligible participants are those presenting with an acute, unexplained worsening of respiratory symptoms, such as dyspnea, hypoxemia, chest pain, or syncope, or those who have a clinical suspicion of pulmonary embolism and are undergoing Computed Tomography Pulmonary Angiography (CTPA) as part of their routine clinical care.

説明

Inclusion Criteria:

  • Age ≥ 18 years
  • Confirmed diagnosis of ILD based on multidisciplinary discussion and HRCT findings, with or without histopathological confirmation
  • Acute unexplained worsening of dyspnea, hypoxemia, chest pain, syncope, or clinical suspicion of PE
  • Undergoing CTPA as part of routine clinical management
  • Provision of informed consent

Exclusion Criteria:

  • Age < 18 years
  • Pregnancy
  • Previously diagnosed acute pulmonary embolism receiving anticoagulant therapy
  • Active malignancy
  • Known inherited or acquired thrombophilia
  • Acute myocardial infarction or ischemic stroke within the previous month
  • Major surgery or trauma within four weeks
  • Severe renal impairment contraindicating contrast-enhanced CTPA

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
ILD with Pulmonary Embolism (Cases)
This group consists of adult patients (aged 18 years and older) with a confirmed diagnosis of Interstitial Lung Disease (ILD) who present with an acute unexplained worsening of respiratory symptoms (such as dyspnea, hypoxemia, chest pain, or syncope). These patients undergo Computed Tomography Pulmonary Angiography (CTPA) as part of routine clinical management and are confirmed to have acute pulmonary embolism.
ILD without Pulmonary Embolism (Controls)
This group consists of adult patients (aged 18 years and older) with a confirmed diagnosis of Interstitial Lung Disease (ILD) who present with an acute unexplained worsening of respiratory symptoms (such as dyspnea, hypoxemia, chest pain, or syncope). These patients undergo Computed Tomography Pulmonary Angiography (CTPA) as part of routine clinical management but have negative findings, confirming the absence of acute pulmonary embolism.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Presence of Acute Pulmonary Embolism
時間枠:Baseline
The primary outcome is the binary assessment (presence or absence) of an acute pulmonary embolism, which is definitively diagnosed and confirmed using Computed Tomography Pulmonary Angiography (CTPA) imaging.
Baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Rate of Admission to the Respiratory Intensive Care Unit (RICU)
時間枠:From hospital admission to hospital discharge, assessed up to 30 days.
The proportion of patients requiring admission to the Respiratory Intensive Care Unit (RICU) for advanced management during their acute worsening respiratory episode.
From hospital admission to hospital discharge, assessed up to 30 days.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2027年8月1日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2026年7月22日

QC基準を満たした最初の提出物

2026年7月22日

最初の投稿 (実際)

2026年7月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月27日

QC基準を満たした最後の更新が送信されました

2026年7月22日

最終確認日

2026年7月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する